Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05300984
Other study ID # 22.01.AMZ
Secondary ID 22.0052-23
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2022
Est. completion date May 16, 2022

Study information

Verified date April 2023
Source Amazentis SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effect of cosmetic products with two different concentrations of the active on skin aging and in acting on the mitochondrial health of skin in comparison to a placebo product.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date May 16, 2022
Est. primary completion date May 10, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria: - Written Informed Consent to participate in the study - Willingness to actively participate in the study and to come to the scheduled visits - Female - From 50 to 75 years of age - Visible wrinkle in the face (grade 3 to 6 according to proderm scale) see Appendix 2 - Healthy skin in the test areas - Vaccination of tetanus within the last 10 years (for biopsy sub group) Exclusion Criteria: - Female subjects: Pregnancy or lactation - Drug addicts, alcoholics - AIDS, HIV-positive or infectious hepatitis - Conditions which exclude a participation or might influence the test reaction/evaluation - Participation or being in the waiting period after participation in cosmetic and/or pharmaceutical studies pertaining to the test area - Cancer not being diagnosed as cured and requiring chemotherapy, irradiation and/or hormonal treatment within the last 2 years - Diabetes mellitus (type 1 and 2) - One of the following illnesses with reduced physical capability/fitness: asthma (symptom-free allergic asthma is not an exclusion criterion), hypertension, cardiovascular diseases - Documented allergies to cosmetic products and/or ingredients, skin care and/or skin cleansing products - Intolerability against adhesive dressing (e.g. acrylate) - Active skin disease at the test area - Regular use of tanning beds - Wounds, moles, tattoos, scars, irritated skin, excessive hair growth, etc. at the test area that could influence the investigation - Any topical medication at the test area within the last 3 days prior to the start of the study - Medical treatment for wrinkle reduction (e.g. peeling with vitamin A or fruit acids) on the face within the last 2 weeks prior to the start of the study - Systemic therapy with immuno-suppressive drugs (e.g. corticosteroids) and/or antihistamines (e.g. antiallergics) within the last 7 days prior to the start of the study - Systemic therapy with anti-phlogistic agents or analgetics (e.g. diclophenac), except for minor pain relief medicine like paracetamol within the last 3 days prior to the start of the study - Therapy with antibiotics within the last 2 weeks prior to the start of the study - Regular medication with anti-coagulating drugs like AspirinĀ®, MacumarĀ®, etc. (e.g. for thrombosis prophylaxis) within up to 15 days prior to the taking of the biopsies - Past cosmetic surgery procedure in the test area (e.g. laser, facelift) - History of complications at wound healing (e.g. keloids, hypertrophic scars or contracture scar)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Topical Placebo Cream
cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
Topical Cream with 0.5% Active
cosmetic cream to be applied topically on face and forearms twice/daily using split/face design
Topical Cream with 1% Active
cosmetic cream to be applied topically on face and forearms twice/daily using split/face design

Locations

Country Name City State
Germany proderm GmbH Schenefeld

Sponsors (2)

Lead Sponsor Collaborator
Amazentis SA proDERM GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in skin mitochondrial health and biological age (assessed on skin biopsies) after 8 weeks 8 weeks
Primary Change from baseline in skin barrier function (assessed on transepidermal waterloss by Tewameter [g/(m²h)]) after 8-weeks 8 weeks
Secondary Change from baseline in skin barrier function (assessed on transepidermal waterloss by Tewameter [g/(m²h)]) after 2-weeks 2-weeks
Secondary Change from baseline in skin hydration (assessed on skin capacitance by Corneometer [a.u.]) after 2 and 8 weeks 8 weeks
Secondary Change from baseline in pigmentation (assessed on skin color by Spectrophotometer) after 2 and 8 weeks 8 weeks
Secondary Change from baseline in skin firmness by Cutometer [mm] after 2 and 8 weeks 8 weeks
Secondary Change from baseline in skin elasticity by Cutometer after 2 and 8 weeks 8 weeks
Secondary Change from baseline in skin layer thickness and undulation index of DEJ (assessed on Line field confocal Optical Coherence Tomography Image analysis) after 8 weeks for both groups or after 2 and 8 weeks 8 weeks
Secondary Change from baseline for wrinkles and fine lines (assessed on Colorface Image analysis) after 2 and 8 weeks 8 weeks
Secondary Subjective Evaluation of product traits assessed via questionnaire after 2 and 8 weeks 2 and 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04276753 - A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects N/A
Completed NCT06125912 - A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging N/A
Completed NCT02580370 - Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines Phase 3
Recruiting NCT01583478 - Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Phase 4
Completed NCT02003833 - Poly-L-lactic Acid for Skin Quality Phase 4
Completed NCT01447342 - A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines Phase 2/Phase 3
Completed NCT00986570 - Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face Phase 3
Completed NCT00974480 - Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging N/A
Completed NCT00272610 - Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin Phase 2
Recruiting NCT03730649 - Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure Early Phase 1
Completed NCT03312543 - Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles N/A
Active, not recruiting NCT05349799 - TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines N/A
Completed NCT03677258 - Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy N/A
Withdrawn NCT05854628 - The Role of Red Flavonoid in Photoaging N/A
Completed NCT01981980 - Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation N/A
Not yet recruiting NCT00767156 - Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging N/A
Recruiting NCT05813054 - Clinical Study to Evaluate the Anti-aging Efficacy of Dermial® N/A
Not yet recruiting NCT04485091 - TCA Peel and Photobiomodulation for Hand Rejuvenation Phase 2
Completed NCT05457491 - Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE) Phase 1
Completed NCT01237977 - Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines Phase 3